Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 11:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Atazanavir 300 mg Clear all
Completed Phase 3 Interventional Results available

Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults

NCT01967940
View directory record Official record
Conditions
HIV, HIV Infections, Acquired Immunodeficiency Syndrome
Interventions
TAF, Placebo, E/C/F/TAF, Current failing ARV regimen, ATV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
5
States / cities
Ft. Pierce, Florida • West Palm Beach, Florida • Wilton Manors, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Sep 28, 2026, 11:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

GSK1349572 Drug Interaction Study With Atazanavir/Ritonavir and Atazanavir

NCT00883935
View directory record Official record
Conditions
Healthy Volunteer
Interventions
GSK1349572, Atazanavir 300 mg, Atazanavir 400 mg, Ritonavir
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 21, 2009 · Synced Sep 28, 2026, 11:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence Study of Atazanavir 300 mg Capsule

NCT00393328
View directory record Official record
Conditions
HIV Infections
Interventions
Atazanavir + Ritonavir
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 50 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Hamilton, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 7, 2011 · Synced Sep 28, 2026, 11:15 PM EDT
Completed No phase listed Observational Results available

Impact of Antiretroviral Therapy on Metabolic, Skeletal, and Cardiovascular Parameters

NCT00851799
View directory record Official record
Conditions
HIV Infection
Interventions
Emtricitabine/tenofovir disoproxil fumarate, Ritonavir, Atazanavir, Raltegravir, Darunavir
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years and older
Enrollment
334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
26
States / cities
Los Angeles, California • San Francisco, California • Torrance, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2016 · Synced Sep 28, 2026, 11:15 PM EDT
Completed Phase 2 Interventional Results available

Safety of EVG+RTV Administered With Other Antiretroviral Agents for the Treatment of HIV-1 Infection

NCT00445146
View directory record Official record
Conditions
HIV Infections
Interventions
EVG, RTV, ARV regimen
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
Not listed
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
47
States / cities
Pheonix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 44 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2016 · Synced Sep 28, 2026, 11:15 PM EDT
Terminated Phase 4 Interventional

Pharmacokinetic Study of Two HIV Protease Inhibitors in Patients

NCT00420355
View directory record Official record
Conditions
HIV Infection
Interventions
atazanavir, lopinavir/ritonavir
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 60 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Feb 5, 2009 · Synced Sep 28, 2026, 11:15 PM EDT
Completed Phase 4 Interventional Results available

Atazanavir/Ritonavir, Once Daily + Raltegravir, Twice Daily, Switch Study in HIV-1-Infected Patients

NCT01332227
View directory record Official record
Conditions
HIV, Combination Therapy
Interventions
Atazanavir, Ritonavir (heat-stable), Raltegravir, Tenofovir/Emtricitabine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
8
States / cities
Little Rock, Arkansas • Palm Springs, California • San Francisco, California + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2015 · Synced Sep 28, 2026, 11:15 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of COBI-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

NCT01108510
View directory record Official record
Conditions
HIV, HIV Infections
Interventions
COBI, RTV, ATV, FTC/TDF, COBI placebo, RTV placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
698 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
64
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 42 more
Source: ClinicalTrials.gov public record
Updated May 22, 2016 · Synced Sep 28, 2026, 11:15 PM EDT
Completed Phase 4 Interventional Results available

Study of Reyataz in HIV-infected Patients With Lipodystrophy Syndrome

NCT00135356
View directory record Official record
Conditions
HIV-Associated Lipodystrophy Syndrome
Interventions
Atazanavir (ATV) + ritonavir (RTV), continuation of backbone 2 nucleoside reverse transcriptase inhibitor (NRTIs), continuation of current HAART (boosted protease inhibitor [PI] combination + 2 NRTIs)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
4
States / cities
Fort Lauderdale, Florida • Honolulu, Hawaii • Huntersville, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated May 6, 2010 · Synced Sep 28, 2026, 11:15 PM EDT
Terminated Phase 4 Interventional Results available

Switching From Efavirenz to Atazanavir/ Ritonavir in HIV-infected Subjects With Good Virologic Suppression

NCT01194856
View directory record Official record
Conditions
HIV Infection, Mitochondrial Dysfunction
Interventions
Atazanavir/ritonavir, Efavirenz
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 10, 2017 · Synced Sep 28, 2026, 11:15 PM EDT
Completed Phase 3 Interventional

Atazanavir or Boosted Atazanavir Substitution for Ritonavir Boosted PI in Patients With Hyperlipidemia

NCT00160329
View directory record Official record
Conditions
Hyperlipidemia, HIV Infections
Interventions
Atazanavir
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jul 20, 2011 · Synced Sep 28, 2026, 11:15 PM EDT
Completed Phase 1 Interventional Results available

Pharmacokinetics of Atazanavir/Ritonavir in HIV-1 Infected Pregnant Women

NCT00326716
View directory record Official record
Conditions
HIV Infection
Interventions
Atazanavir + Ritonavir + Combivir
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older · Female only
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
West Palm Beach, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 15, 2011 · Synced Sep 28, 2026, 11:15 PM EDT
Completed Not applicable Interventional Results available

Pilot Study of a Raltegravir Based NRTI Sparing Regimen

NCT00814879
View directory record Official record
Conditions
Acquired Immune Deficiency Syndrome, AIDS, Human Immunodeficiency Virus, HIV Infections
Interventions
Raltegravir, Atazanavir, Standard treatment regimen
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
5
States / cities
New Haven, Connecticut • Waterbury, Connecticut • West Haven, Connecticut + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2016 · Synced Sep 28, 2026, 11:15 PM EDT
Completed Phase 3 Interventional Results available

Switch to Atazanavir and Brachial Artery Reactivity (SABAR) Study

NCT00225017
View directory record Official record
Conditions
HIV Infection, Hyperlipidemia
Interventions
Atazanavir, current antiretroviral regimen
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
5
States / cities
San Diego, California • Chicago, Illinois • Indianapolis, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2012 · Synced Sep 28, 2026, 11:15 PM EDT
Terminated Phase 2 Interventional Results available

Phase IIB Pilot of Atazanavir + Raltegravir

NCT00768989
View directory record Official record
Conditions
HIV
Interventions
Atazanavir, Raltegravir, Ritonavir, Tenofovir/Emtricitabine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
9
States / cities
Phoenix, Arizona • New Haven, Connecticut • Washington D.C., District of Columbia + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2012 · Synced Sep 28, 2026, 11:15 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of E/C/F/TDF Versus RTV-Boosted ATV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment-Naive Women

NCT01705574
View directory record Official record
Conditions
Acquired Immunodeficiency Syndrome, HIV Infections
Interventions
E/C/F/TDF, ATV, RTV, FTC/TDF, E/C/F/TDF Placebo, ATV Placebo, RTV Placebo, FTC/TDF Placebo, E/C/F/TAF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older · Female only
Enrollment
583 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
41
States / cities
Los Angeles, California • Sacramento, California • Washington D.C., District of Columbia + 31 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2019 · Synced Sep 28, 2026, 11:15 PM EDT
Completed Phase 3 Interventional Results available

Roll-Over Protocol To Provide Atv And/Or Truvada For Extended Access

NCT01003990
View directory record Official record
Conditions
HIV
Interventions
Atazanavir, Atazanavir/Ritonavir, Tenofovir/Emtricitabine, Lopinavir/ritonavir
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
16 Years and older
Enrollment
710 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2016
U.S. locations
12
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated May 10, 2017 · Synced Sep 28, 2026, 11:15 PM EDT
Completed Phase 4 Interventional Results available

Nevirapine vs. Atazanavir Boosted With Ritonavir on a Background of Truvada in Human Immunodeficiency Virus (HIV) Infected Naive Patients (NEwArT)

NCT00552240
View directory record Official record
Conditions
HIV Infections
Interventions
tenofovir DF 300 mg QD, emtricitabine 200 mg QD, Nevirapine 200 mg BID, Atazanavir 300 mg, Ritonavir 100 mg
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
19
States / cities
Beverly Hills, California • Los Angeles, California • Denver, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2014 · Synced Sep 28, 2026, 11:15 PM EDT
Completed Phase 3 Interventional Results available

Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV

NCT00035932
View directory record Official record
Conditions
HIV Infections
Interventions
Atazanavir + ritonavir + tenofovir + nucleoside, Atazanavir + saquinavir + tenofovir + nucleoside, Lopinavir/ritonavir + tenofovir + nucleoside
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
16 Years and older
Enrollment
571 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
29
States / cities
San Francisco, California • Torrance, California • Boulder, Colorado + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2010 · Synced Sep 28, 2026, 11:15 PM EDT
Completed Phase 3 Interventional Results available

Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF

NCT02121795
View directory record Official record
Conditions
HIV-1 Infection
Interventions
FTC/TDF, F/TAF, Allowed third antiretroviral agent, FTC/TDF Placebo, F/TAF Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
668 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
57
States / cities
Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 40 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2020 · Synced Sep 28, 2026, 11:15 PM EDT
Completed Phase 2 Interventional Results available

TMC125-TiDP2-C238: An Exploratory Pharmacokinetics, Safety and Anti-HIV Activity Study of Etravirine (ETR) When Given With Boosted Atazanavir (ATV/Rtv) at Two Different Doses and 1 Nucleoside Reverse Transcriptase Inhibitor (NRTI) in Treatment Experienced HIV Patients

NCT00896051
View directory record Official record
Conditions
HIV Infections, Acquired Immunodeficiency Syndrome
Interventions
Atazanavir (ATV) 300 mg, Atazanavir (ATV) 400 mg, Ritonavir (rtv) 100 mg, Nucleo(side)/(tide) reverse transcriptase inhibitors (NRTIs), Etravirine (ETR) 200 mg, Tenofovir disoproxil fumarate (TDF) 300 mg
Drug
Lead sponsor
Janssen R&D Ireland
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
10
States / cities
Little Rock, Arkansas • Bakersfield, California • Beverly Hills, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2013 · Synced Sep 28, 2026, 11:15 PM EDT
Completed Phase 3 Interventional Results available

Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC

NCT02469246
View directory record Official record
Conditions
HIV-1 Infection
Interventions
F/TAF, ABC/3TC, ABC/3TC Placebo, F/TAF Placebo, 3rd ARV agent
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
567 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
34
States / cities
Phoenix, Arizona • Beverly Hills, California • La Jolla, California + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2019 · Synced Sep 28, 2026, 11:15 PM EDT
Completed Phase 3 Interventional Results available

Regimen Switch to Dolutegravir/Lamivudine Fixed Dose Combination From Current Antiretroviral Regimen in HIV-1 Infected and Virologically Suppressed Adults (SALSA)

NCT04021290
View directory record Official record
Conditions
HIV Infections
Interventions
DTG/3TC FDC, CAR
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
493 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
16
States / cities
Los Angeles, California • Newport Beach, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2023 · Synced Sep 28, 2026, 11:15 PM EDT
Completed Phase 3 Interventional Results available

Comparative Study of Three NNRTI-Sparing HAART Regimens

NCT00811954
View directory record Official record
Conditions
HIV Infection
Interventions
Emtricitabine/tenofovir disoproxil fumarate, Raltegravir, Darunavir, Ritonavir, Atazanavir
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years and older
Enrollment
1,814 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
55
States / cities
Birmingham, Alabama • Long Beach, California • Los Angeles, California + 39 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2014 · Synced Sep 28, 2026, 11:15 PM EDT